In silico analysis of MYCN non-amplified NB (to assess PLCL1 function independent of MYCN) in different independent patient cohorts revealed decreased expression of PLCL1 in stage 4 disease, and decreased patient survival associated with low expression of this gene. The gene discussed is PLCL1; the disease is neuroblastoma.